Specialty pharmacy trade deals are shifting from the drug journey to the patient journey. Asembia’s Ray Tancredi explains why filling 50 of 100 scripts is close to the industry norm and what that means for contracts. Watch the full interview: https://t.co/KmcdJOCg6o
Distributors handle roughly 96% of U.S. medication volume from more than 1,400 manufacturers, per an HDA Research Foundation and Deloitte report. In a new PC byline, McKesson’s Gene Cavacini on what cell and gene therapies will ask of that network next. https://t.co/yRfprisa4U
Where will complex therapies be dispensed, and who will manage the channel? Our new Executive Conversations series puts those questions to trade and channel leaders from Regeneron, Asembia, Orsini and more. https://t.co/8T9mA88wHd
#Pharma
In a Cencora survey, 74% of payers set CGT prior auth criteria more restrictive than the label.
Cencora’s Louis Cicchini on why access planning has to start in development.
🔗 Find the early decisions that shape coverage: https://t.co/5Vdq18B0rJ
#MarketAccess
Renovating an idle U.S. plant takes about six months. Building a new one can take four to six years. Brian Doty, Ph.D., of the API Innovation Center tells Pharmaceutical Commerce why that gap matters for reshoring generics, where margins are thin: https://t.co/oKBi0AUNml
#Pharma
Pharma has a “data debt” problem, and AI is about to raise the interest rate, says Beghou’s Clare Gora. Her fix: tackle one business problem at a time and build assets that carry over to the next. https://t.co/5X96HNcX4s
#Pharma
Lilly brings Zepbound and Foundayo to Hims & Hers at self-pay prices; Hims & Hers pledges never to compound them. Plus: FDA adds an NAION warning across the GLP-1 class. Both on this week’s Pharma Pulse: https://t.co/CwqKg4JTYM
What if claims intelligence shaped how affordability programs are designed & priced, not just defended?
@Paysign’s Matt Turner on ClaimGuardRx’s long-term vision.
📽️ Hear where the platform is headed next: https://t.co/oY6G3aqUCS
#MarketAccess
CVS Health’s newly announced breakup may change who owns the pharmacy. Does it change who controls access to medicines? Thani Jambulingam, PhD, weighs in: https://t.co/AZoHrl8HBB
#Pharma#CVS
Spotting maximizer activity is only half the job. Responding fast is the other half.
@Paysign’s Bryan Dennison on the purpose-built LLM behind ClaimGuardRx.
📽️ See how it helps teams close the loop: https://t.co/pLNITnZL7f
#MarketAccess
Diversion & fraud are draining copay programs, & teams lack a quick way to quantify either.
@Paysign’s Logan Melchione on getting answers, with supporting data, in seconds.
📽️ Watch how more copay dollars reach patients: https://t.co/l1nBHtBgFz
#MarketAccess
NEW — Ed Schoonveld on why Congress may be a lame duck on drug pricing, and how full price transparency would make differential pricing impossible to sustain.
Read the latest piece: https://t.co/cc10cLilSj
#Pharma#WHO#MFN
More therapies, channels & temperature profiles are pushing pharma warehouses past what their WMS was built for.
How to tell if yours can keep up: https://t.co/89m0TtiaNw
Pharma’s AI push has made each commercial team faster, while the handoffs between insights, marketing, medical and the field look about the same. A new piece in Pharmaceutical Commerce argues the workflow is what needs redesigning next: https://t.co/Y2yRUuGd8y
Sound pricing and contracting decisions can still undercut a launch. IQVIA’s Matthew Champion and Kunal Akwalia explain why: https://t.co/o2YydbwG2e
#Pharma
Lower drug prices address only part of what patients pay. Accessia Health’s Tiara Green explains why premiums, deductibles and payer policies can still make it hard to stay on treatment heading into 2027: https://t.co/jPtFzVYOSn
Bolting AI onto legacy supply chain systems risks fragmented data, hallucinations & limited auditability.
PAXAFE’s Mark Talens on the guardrails that build trust.
📽️ Hear what AI should act on, & what it shouldn’t: https://t.co/Jv2SDLymgb
#Pharma#AI
Biologics have raised the stakes of every cold chain excursion, ELPRO CEO Frederik Dresen told Pharmaceutical Commerce. He explains why visibility alone won’t define the cold chain’s next phase: https://t.co/WeMSIxRSCg
#Pharma#ColdChain
Imported pharma inventory in a Foreign-Trade Zone generally owes no US duty until it enters domestic commerce. We break down how FTZs fit into inventory strategy, with a case study on Frontier Scientific Solutions’ Wilmington, NC, facility: https://t.co/6D9MZpdcHD
Emerging biotechs and large pharma start a launch from different positions. Jon Hamrick of Curatio Advisors explains how product attributes, company size and stakeholder alignment shape commercialization strategy. https://t.co/eO7QnBvkGQ